This site is intended for US healthcare professionals.
To report an adverse reaction or product complaint, call 1-888-BLUPRNT, option 2, or visit or contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Clinical trials

Explore clinical trials in the pipeline of Blueprint Medicines

  • Clinical Trial Name
  • Title
  • Status
  • Phase
  • Study number
  • Clinical Trial Name PATHFINDER: A Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis
  • Title A Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), a Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
  • Status Active, Fully enrolled
  • Phase Phase 2
  • Study number NCT03580655
  • Clinical Trial Name PIONEER: A Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients with Indolent Systemic Mastocytosis
  • Title A Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), a Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis
  • Status Active, Fully enrolled
  • Phase Phase 2
  • Study number NCT03731260
  • Clinical Trial Name HARBOR: A Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients with Indolent Systemic Mastocytosis
  • Title A Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
  • Status Active, Recruiting
  • Phase Phase 2/3
  • Study number NCT04910685
  • Clinical Trial Name prospector
  • Title Screening Study Evaluating the Prevalence of the KIT D816V Mutation in Patients With Systemic Mast Cell Activation
  • Status Active, Recruiting
  • Phase Observational
  • Study number NCT04811365
  • Clinical Trial Name
  • Title
  • Status
  • Phase
  • Study number
  • Clinical Trial Name ARROW: A Study of the Highly selective RET Inhibitor, Pralsetinib (BLU-667), in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
  • Title A Study of the Highly Selective RET Inhibitor, Pralsetinib (BLU-667), in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
  • Status Active, Fully enrolled
  • Phase Phase 1/2
  • Study number NCT03037385
  • Clinical Trial Name AcceleRET-Lung: A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
  • Title A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
  • Status Active, Recruiting
  • Phase Phase 3
  • Study number NCT04222972
  • Clinical Trial Name AcceleRET-MTC: A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC)
  • Title A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC)
  • Status Not yet recruiting
  • Phase Phase 3
  • Study number NCT04760288
  • Clinical Trial Name
  • Title
  • Status
  • Phase
  • Study number
  • Clinical Trial Name SYMPHONY: A Study Targeting EGFR Resistance Mechanisms in NSCLC
  • Title A Study Targeting EGFR Resistance Mechanisms in NSCLC
  • Status Active, Recruiting
  • Phase Phase 1/2
  • Study number NCT04862780
  • Clinical Trial Name HARMONY: A Study of BLU-701 in EGFR-mutant NSCLC
  • Title A Study of BLU-701 in EGFR-mutant NSCLC
  • Status Active, Recruiting
  • Phase Phase 1/2
  • Study number NCT05153408
  • Clinical Trial Name
  • Title A clinical trial for people with non-small cell lung cancer harboring EGFR exon 20 insertion mutations
  • Status Active, Recruiting
  • Phase Phase 1/2
  • Study number NCT05241873
  • Clinical Trial Name
  • Title
  • Status
  • Phase
  • Study number
  • Clinical Trial Name ROVER: A Study of Avapritinib in Pediatric Patients with Solid Tumors Dependent on KIT or PDGFRA Signaling
  • Title A Study of Avapritinib in Pediatric Patients with Solid Tumors Dependent on KIT or PDGFRA Signaling
  • Status Active, Recruiting
  • Phase Phase 1/2
  • Study number NCT04773782
  • Clinical Trial Name
  • Title
  • Status
  • Phase
  • Study number
  • Clinical Trial Name
  • Title A clinical trial for people with cyclin E aberrant cancers and estrogen receptor-positive, HER2-negative breast cancer
  • Status Active, Recruiting
  • Phase Phase 1
  • Study number NCT05252416

Contact Blueprint Medicines

Submit a medical inquiry Request information about our products.

Contact our medical information teammedinfo@blueprintmedicines.com or 1-888-258-7768 (Option 2)

Blueprint Medicines is a pharmaceutical company focusing on the research, development, and commercialization of products in oncology, hematology, and rare diseases. This website is for US healthcare professionals for educational purposes only. Scientific information and data may include investigational use(s) of compounds for which efficacy and safety have not been established. Blueprint Medicines does not promote or endorse the use of its products in a manner not consistent with the approved label.